Breath analysis to detect fungal infections in leukemia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with leukemia who are at high risk for invasive fungal infections (IFI) due to chemotherapy-induced neutropenia. It aims to identify specific volatile biomarkers associated with IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS). The approach is non-invasive, which is crucial for patients who cannot undergo traditional diagnostic procedures due to severe thrombocytopenia. By analyzing breath samples, the study seeks to improve the accuracy of IFI diagnosis in this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of acute leukemia
* Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer
* Neutropenia (\<500/µl) present at inclusion or planned chemotherapy with expected neutropenia (\<500/µl) for more than 7 days

Exclusion Criteria:

* Unable to follow instructions for breath analysis
* Anatomic abnormalities precluding the use of a mouthpiece for breath analysis

Where it's running

• University Hospital of Zurich
  Zurich, Canton of Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Jeremy Deuel, PD Dr. — University of Zurich
• Study coordinator: Jeremy Deuel, PD Dr.
• Email: jeremy.deuel@usz.ch
• Phone: +41 44 255 11 11

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Triple-drug approach for AML using eganelisib with azacitidine and venetoclax

  This early-stage trial tests whether adding eganelisib to azacitidine and venetoclax can be safe and show signs of benefit in adults with acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07439211

• Combining Venetoclax with Intensive Therapy for Acute Myeloid Leukemia Patients

  This study is testing if adding a drug called Venetoclax to standard chemotherapy can help newly diagnosed acute myeloid leukemia patients who aren't responding well to their initial treatment.

  Recruiting Affiliated Hospital of Nantong University · Nantong, Jiangsu · NCT06643962

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• CIML NK cells combined with venetoclax for treating acute myeloid leukemia

  This study is testing a new treatment using special immune cells and a medication to see if it can help people with acute myeloid leukemia feel better.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06152809

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.